Results
Confo Therapeutics enters clinical stage with drug for neuropathic pain
Confo Therapeutics is a rising star in Belgium, featured on several local and international lists of up-and-coming biotechs. The company, launched in 2015 as a VUB/VIB spin-off is now taking the big step from the preclinical to the clinical stage with a GPCR drug for neuropathic pain.
Read more
VUB's expertise in computer-generated holography
The department of Electronics and Informatics (ETRO) of the VUB and imec built-up a reputation in the domain of computer-generated holography. This technology is key to providing high-end media content for holographic display and printing.
Read more
Radical new technology to diagnose and monitor can help millions of diabetics
More than 500 million people worldwide suffer from diabetes. Today the monitoring process is expensive and time consuming and not all patients can be reached.
Read more
From demolition towards preservation: A paradigm shift for Brussels building sector
Why are buildings being demolished and how can we influence decision making processes of building teams? How do narratives on the city and architectural taste influence whether a building will be demolished?
Read more
VUB invests in applied research with IOF funding
The Industrial Research Fund (IOF) is an earmarked University Association Fund that is annually fed with a block grant from the Flemish Government.
Read more
Next step in corrosion prevention for cars
Nowadays new cars mainly consist of the very light metal aluminum and magnesium, which are not directly connected to corrosion. But that isn't quite right.
Read more
VUB scientists can re-implant previously collected testicular tissue in men after cancer treatment
The VUB research group Biology of the Testis (BITE) of Prof. Ellen Goossens (together with UZ Brussel) will be the first worldwide to re-implant previously collected testicular tissue in men, who do not produce sperm cells as a result of cancer treatment at a young age.
Read more
Start-up Esobiotec pursues affordable cancer immunotherapy
The VUB is an Urban Engaged University that is firmly committed to the fight against cancer through scientific research.
Read more
eTheRNA announces research agreement with Merck to access mRNA technologies
eTheRNA immunotherapies announces the start of a strategic partnership with Merck with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA’s proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck.
Read more
Brussels grants spin-off Axiles Bionics
VUB spin-off Axiles Bionics won the Innovative Starters Award 2021. With the Innovative Starters Award (ISA) programme, Innoviris annually supports ambitious start-ups & scale-ups that are striving for an effective strategic breakthrough. Axiles Bionics aims to deve...
Read more